Latest News and Press Releases

Clinical Phase II milestone: All 63 donor-recipient pairs enrolled and treated according to protocol across multiple clinical centers

Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release...

Abu Dhabi, United Arab Emirates and Seoul, South Korea, June 29, 2026 (GLOBE NEWSWIRE) -- Arcera Life Sciences ("Arcera"), a global life sciences company focused on advancing innovative and...

- Phase 3 PROPEL 3 data published today in NEJM were simultaneously presented at ICCBH in a late-breaking oral presentation; presentation includes new arm span Z-score data showing a statistically...

Washington, DC, June 27, 2026 (GLOBE NEWSWIRE) -- The American Nurses Association (ANA) has approved a significant update to its bylaws, expanding membership eligibility to include licensed...

Watsonville, CA, June 26, 2026 (GLOBE NEWSWIRE) -- Nordic Naturals, the #1 selling fish oil brand in the U.S.‡, today announced that its award-winning Ultimate Omega® is a featured ingredient in...

WILMETTE, Ill., June 26, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments...

BEDFORD, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians...

Siren Biotechnology awarded $8M in grant funding from the California Institute for Regenerative Medicine (CIRM) to support clinical development of SRN-101

New analyses from the Phase 3 Vivacity-MG3 study support the impact of nipocalimab in anti-AChR+a, anti-MuSK+b adult patients with generalised myasthenia gravis (gMG) including those early in their...